Eli Lilly and Co. has paid more than $1 billion to settle legal battles over its top-selling drug Zyprexa, and it might have to write another large check soon. But a new lawsuit says the company should have known better.

Two shareholders have accused Lilly executives and directors of recklessly disregarding risks posed by illegal drug marketing tactics, which have been alleged in lawsuits and newspaper articles.